Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

By I. McInnes, A. Kavanaugh, A. Gottlieb, L. Puig, P. Rahman, C. Ritchlin, C. Brodmerkel, Shu Li, Yuhua Wang, A. Mendelsohn and 1 more. The Lancet, 2013

768 citations recorded by the source corpus.

Subfields: Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/eb3ebfa83f57551ffa4ab337ab5debc59ef905e0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. McDermott
2. Lisa M Sedger

Citations in the corpus

• TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. (2014, background): “Alternatively, other cytokine neutralizing mAbs might be beneficial, as it has also been demonstrated that anti-TNF non-responding psoriatic arthritis patients experience benefit from ustekinumab (Stelara), a new IL-12/23 p40 neutralizing mAb [302,303].”